ArticleTransplant infectious disease : an official journal of the Transplantation Society
Characterization of Beta-Lactam Allergy and Outcomes Associated With Perioperative Antibiotic Choice in Renal Transplant Recipients.
Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Abdominal Organ Transplantation: Noteworthy Literature in 2025.Seminars in cardiothoracic and vascular anesthesia · 2026Review
- Characterization of Beta-Lactam Allergy and Outcomes Associated With Perioperative Antibiotic Choice in Renal Transplant Recipients.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBeta-lactam allergies (BLAs) are commonly reported and may include true allergy or adverse effects. BLAs can lead to the use of suboptimal antimicrobials, resulting in adverse outcomes. At our institution, cefazolin is the preferred surgical prophylaxis for renal transplant (RT), with clindamycin used for BLAs. There is limited data available examining outcomes with the use of non-standard surgical site prophylaxis in RT.
methodsThis study evaluated 1523 adult RT patients from December 1, 2019 to December 1, 2024, with 257 (16.9%) having a documented BLA. BLA reactions were classified as immediate/allergic and non-allergic. Secondary outcomes included surgical site infections (SSIs) within 30 days and Clostridium difficile within 60 days, and were compared between groups that received cefazolin and clindamycin.
resultsA total of 13.0% of the population had true allergic-type reaction. The most common BLA was to penicillins (71.2%), then cephalosporins (46%) or multiple classes (10.8%). Allergic-type reactions were reported by 186 (72.4%), and non-allergic reactions were reported by 35 (13.6%), with 12 patients reporting both types, and 24 without recorded reactions. The most common immediate/allergic reaction was hives/rash (155 patients). The most common non-allergic reaction was gastrointestinal symptoms. For perioperative prophylaxis, 182 patients received clindamycin and 67 received cefazolin. There was no difference in C. difficile in the first 60 days. There was a higher rate of SSI in the first 30 days in patients who received clindamycin (29/182, 15.9%) compared to cefazolin (2/67, 2.99%), p = 0.006.
conclusionBLA is commonly reported, but the type of reactions should be critically evaluated, as non-standard antibiotics may increase SSI risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.